Portfolio of

Transcatheter

Endovascular Anchoring

About

Endoron Medical portfolio of anchoring solutions expand and enhance treatment options available for patients by making current devices better across the aortic continuum from TAVR to EVAR.

Endoron Medical is proud to be awarded a €2.5 million grant by the European Commission under the EIC Accelerator program, European Innovation Council and SMEs Executive Agency (EISMEA)!

The EIC is Europe’s flagship innovation programme to identify, develop and scale up breakthrough technologies and game changing innovations.

The European Innovation Council (EIC) has been established under the EU Horizon Europe programme. It has a budget of €10.1 billion to support game changing innovations throughout the lifecycle from early stage research, to proof of concept, technology transfer, and the financing and scale up of start-ups and SMEs.

The strategy and implementation of the EIC is steered by the EIC Board, which has independent members appointed from the world of innovation (entrepreneurs, researchers, investors, corporates and others from the innovation ecosystem).

Aortoseal

Next Generation Endosuturing

Device for EVAR

Aortodock

Novel Docking Solution for

TAVR

Technology

Endoron portfolio

Transcatheter valve dOCKING SOLUTION

For calcium-independent anchoring and stability

We strive to provide Aortic Regurgitation patients additional treatment options to undergo Transcatheter Valve Replacement with increased anchoring and stability of their implanted valve

Aortodock was developed to create a stable landing zone and docking platform independent of calcium burden, annular shape, or dilation,enabling transcatheter treatment in low-to-no calcium anatomies that currently cannot be reliably addressed with existing valves, reducing the risk of valve embolization and migration

Aortic Regurgitation

Aortic regurgitation (AR) occurs when the aortic valve does not close fully, allowing blood to flow back into the left ventricle during diastole. It arises from valve degeneration, congenital bicuspid morphology, inflammatory or infectious processes, or dilation of the aortic root that prevents proper leaflet coaptation. AR may present acutely or progress over time, driving left‑ventricular enlargement, increased wall stress and eventual systolic dysfunction. In the United States, AR represents one of the most common valvular disorders, with moderate to severe disease present in about one million people, though a substantial proportion remains undiagnosed. Each year, thousands of new cases are identified incidentally through echocardiography or imaging performed for other clinical indications. Treatment pathways vary by severity and ventricular remodeling and include surveillance medication, an intervention with surgical aortic valve replacement(SAVR) or transcatheter aortic valve replacement (TAVR). Advances in trans catheter technology continue to expand treatment options for patients

Aortodock – THE NEED

Transcatheter therapy (e.g., TAVR) for native aortic regurgitation (AR) depends on achieving stable anchoring and a complete circumferential seal between the valve frame and the native annulus. However, AR anatomy lacks the calcification required for radial force fixation. Large, compliant, or elliptical annuli frequently prevent secure engagement of current aortic stenosis-focused devices. In these anatomies, existing TAVR platforms are prone to malposition ,embolization or migration, and paravalvular leak –driving procedural failure and adverse clinical outcomes. This challenge is substantial with most AR patients presenting with anatomy fundamentally beyond device design assumptions due to absent calcium, annular dilation, or high-volume regurgitant flow. These cases can be treated more predictably with dedicated AR‑specific transcatheter valves that use leaflet‑engaging mechanisms rather than calcific fixation. These technologies remain investigational in the United States and require specialized experience and infrastructure not yet widely available

Aortodock – The Solution

Aortodock™ is an anchoring and stabilization system engineered to secure transcatheter valves in low‑calcium anatomy across the aortic regurgitation (AR) to aortic stenosis (AS) continuum. Aortodock is a self-expanding nitinol frame with staples that engage with balloon expansion. The steerable delivery system is designed to permit implant recapturing and repositioning for precise placement. The nitinol frame creates a stable landing zone and docking platform independent of calcium burden, annular shape, or dilation, enabling transcatheter treatment in low-to-no calcium anatomies that currently cannot be reliably addressed with existing AS‑designed valves. Aortodock is intended to reduce the risk of valve embolization and migration while expanding the use of established TAVR platforms into native aortic regurgitation (AR) and low‑calcium aortic stenosis (AS)

AortoDock’s BENEFITS

Redefines TAVR landing zone

Predictable placement

Improved fixation to prevent migration

Suitable for minimally or non-calcified anatomy

Expands the use of existing TAVR devices

Provides more options to physicians and patients

Endograft

fastening

solution

for a complete seal and stability

We strive to provide Aortic Aneurysm patients undergoing Endovascular Aneurysm Repair with a long-lasting sealing and fixation solution for their endograft

Aortoseal was developed to mimic the reliable hand-sewn suturing technique from open surgery, evenly
distributing staples around the circumference of the aorta, creating leak and migration free anastomosis.

Aortic Aneurysms

Aortic aneurysms can occur in any segment of the aorta — from the ascending aorta and arch to the descending thoracic, thoracoabdominal, and abdominal regions. They arise when the aortic wall weakens and expands, creating a risk of rupture and severe internal bleeding. In the United States, an estimated one to two million people are living with an aortic aneurysm, though many remain undiagnosed. Each year, tens of thousands of new thoracic and abdominal aneurysms are identified through imaging performed for other conditions. Treatment approaches vary by location and anatomy and include open surgery and endovascular stent-graft repair (TEVAR/EVAR).

THE NEED

The success of endovascular aortic repair (EVAR/TEVAR) depends on achieving durable fixation and seal between the stent graft and the native aorta. However, aortic anatomy varies widely, and short, angulated, or irregular necks frequently prevent complete apposition of the graft to the vessel wall. In these anatomies, current devices are prone to loss of fixation or seal, resulting in graft migration, endoleaks, elevated sac pressure, and potential rupture. This challenge is substantial: 40%–60% of EVAR candidates present with anatomies outside device instructions for use due to complex proximal necks.

These cases can only be treated in a minimally invasive manner with complex, custom-made, high-cost fenestrated or branched stent grafts that require specialized expertise and infrastructure not available in most hospitals.

THE SOLUTION

Aortoseal™ is a long-lasting fixation and sealing system engineered to secure stent grafts anywhere along the aortic continuum. Its smart multi-stapling mechanism deploys multiple staples simultaneously through the graft and into the aortic wall, creating a true anastomosis that mimics the hand-suturing of open repair. The staples are distributed circumferentially, providing both radial and longitudinal fixation while permanently isolating the aneurysm. Deployment is fast and precise with a single release action.

By delivering robust fixation and complete seal independent of neck length, angulation, or complexity, Aortoseal™ enables endovascular treatment in anatomies that currently require complex, custom-made grafts. The technology is designed to significantly reduce migration, endoleaks, and reinterventions while simplifying procedures across all aortic segments.

Zeroneck implant’s opening and
positioning inside the stent graft
provides a stable structure for the
staples.

Staples are released from
the delivery sheath to be set
perpendicular to the stent
graft, ready to be activated.

To activate the staples the
balloon applies pressure on
the base of each one, pushing
them through the stent graft
and the aortic wall,
all the way to the adventitia.

The eagle-like wings of the staples
are pre-shaped to open up and
“hug” the graft and aortic wall from
both sides, securing sealing and
fixation of the stent graft